LIPELLA PHARMACEUTICALS INC.
Qualité des données : 100%
LIPO
OTC
Manufacturing
Chemicals
0,04 €
▲
0,01 €
(59,09%)
Cap. Boursière: 161 729,0
Prix
0,04 €
Cap. Boursière
161 729,0
Fourchette du Jour
0,01 € — 0,02 €
Fourchette 52 Semaines
0,01 € — 3,17 €
Volume
54
Ouverture 0,01 €
Moyenne 50J / 200J
0,16 €
78,00% below
Moyenne 50J / 200J
0,44 €
92,10% below
Quick Summary
Points Clés
Negative free cash flow of -4,78 M
Capital efficient — spends only 0,00% of revenue on capex
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)19,29%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-252,04%
En dessous de la moyenne du secteur (-53,41%)
ROIC-182,62%
Net Margin-1367,37%
Op. Margin-1387,94%
Sécurité
Debt / Equity
N/A
Current Ratio3,24
Interest CoverageN/A
Valorisation
PE (TTM)
-0,03
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,11
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1364 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 0,0 | -1,5 |
| P/B | 0,1 | 1,6 |
| ROE % | -252,0 | -53,4 |
| Net Margin % | -1367,4 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 19,29% | Revenue Growth (3Y) | 70,66% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 389 783,0 | Net Income (TTM) | -5,33 M |
| ROE | -252,04% | ROA | -175,61% |
| Gross Margin | N/A | Operating Margin | -1387,94% |
| Net Margin | -1367,37% | Free Cash Flow (TTM) | -4,78 M |
| ROIC | -182,62% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3,24 |
| Interest Coverage | N/A | Asset Turnover | 0,13 |
| Working Capital | 1,44 M | Tangible Book Value | 1,49 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,03 | Forward P/E | N/A |
| P/B Ratio | 0,11 | P/S Ratio | 0,41 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -2952,92% | ||
| Market Cap | 161 729,0 | Enterprise Value | -1,69 M |
| Per Share | |||
| EPS (Diluted TTM) | -2,26 | Revenue / Share | 0,08 |
| FCF / Share | -1,03 | OCF / Share | -1,03 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,00% | FCF Conversion | 89,61% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | 536 357,0 | 449 617,0 | 184 156,0 |
| Net Income | -5,02 M | -4,62 M | -2,60 M |
| EPS (Diluted) | -4,79 | -0,77 | -0,64 |
| Gross Profit | — | — | — |
| Operating Income | -5,08 M | -4,75 M | -2,59 M |
| EBITDA | — | — | — |
| R&D Expenses | 3,61 M | 3,04 M | 2,55 M |
| SG&A Expenses | — | — | — |
| D&A | 2 886,0 | 1 685,0 | — |
| Interest Expense | 10 848,0 | 10 848,0 | 9 612,0 |
| Income Tax | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Total Assets | 2,67 M | 3,58 M | 5,95 M |
| Total Liabilities | 754 417,0 | 432 726,0 | 1,27 M |
| Shareholders' Equity | 1,92 M | 3,14 M | 4,68 M |
| Total Debt | — | — | — |
| Cash & Equivalents | 2,18 M | 3,29 M | 5,12 M |
| Current Assets | 2,62 M | 3,43 M | 5,80 M |
| Current Liabilities | 754 417,0 | 385 355,0 | 1,18 M |
{"event":"ticker_viewed","properties":{"ticker":"LIPO","listing_kind":"stock","pathname":"/stocks/lipo","exchange":"OTC","country":"US"}}